Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 18/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371435 | 0.90 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5369525 | 0.88 | AGPAT2 (0.83) | AGPAT2 | |
| SCHEMBL14439013 | 0.87 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5379798 | 0.83 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5385015 | 0.78 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL6479133 | 0.75 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL5385802 | 0.73 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL4277512 | 0.72 | AGPAT2 (1.00) | AGPAT2MAPT | |
| SCHEMBL14254295 | 0.72 | EGFR (0.50) | AGPAT2PDGFRBPDGFRAMAPT | |
| SCHEMBL5375395 | 0.72 | AGPAT2 (1.00) | AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050182102-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182102-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 24/4885PDGFRB 594/4885PDGFRA 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.